We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Secukinumab 300 mg administered with an auto-injector ...

SAN DIEGO — For patients with active psoriatic arthritis, the human interleukin (IL)-17A antagonist secukinumab (Cosentyx, Novartis Pharmaceuticals), administered by subcutaneous injection, ...

Secukinumab is approved for use among patients with enthesitis-related arthritis (ERA) aged 4 years and up, and those with psoriatic arthritis (PsA) who are at least 2 years old. The FDA has approved ...

Please provide your email address to receive an email when new articles are posted on . Secukinumab is efficacious in children and adolescents with psoriatic arthritis and enthesitis-related arthritis ...

Acute psoriasis on elbows is an autoimmune incurable dermatological skin disease. Large red, inflamed, flaky rash on the knees. Joints affected by psoriatic arthritis. Secukinumab vs adalimumab for ...

The US Food and Drug Administration (FDA) has approved secukinumab (Cosentyx, Novartis) for the treatment of active enthesitis-related arthritis (ERA) in children and adolescents age 4 years and older ...

psoriasis-Secukinumab-1114 All subjects successfully self-administered treatment at Week 1, without critical use-related hazards. Secukinumab, a drug currently in clinical trials for treatment of ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

The results from an analysis of patients from 12 rheumatology centers treated with secukinumab for psoriatic arthritis were in line with earlier pivotal trials, the researchers said. A recent study of ...

In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of secukinumab, an anti–interleukin ...

Secukinumab (Cosentyx) showed promise as a steroid-sparing agent in giant cell arteritis, a researcher reported here. In a phase II trial that enrolled 52 patients, 70.1% (95% CI 51.6-84.9) of those ...